{"id":482226,"date":"2021-04-27T08:04:13","date_gmt":"2021-04-27T12:04:13","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/clinical-data-shows-noxopharms-veyonda-may-prevent-cytokine-storm\/"},"modified":"2021-04-27T08:04:13","modified_gmt":"2021-04-27T12:04:13","slug":"clinical-data-shows-noxopharms-veyonda-may-prevent-cytokine-storm","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/clinical-data-shows-noxopharms-veyonda-may-prevent-cytokine-storm\/","title":{"rendered":"Clinical Data Shows Noxopharm\u2019s Veyonda\u00ae May Prevent Cytokine Storm"},"content":{"rendered":"

<\/p>\n

Clinical Data Shows Noxopharm\u2019s Veyonda\u00ae May Prevent Cytokine Storm<\/b><\/p>\n

SYDNEY–(BUSINESS WIRE<\/a>)–
\nAustralian clinical-stage drug development company Noxopharm Limted<\/a> (ASX:NOX) today announced that in a cohort of 18 patients with moderately severe cases of COVID-19, interim data in its NOXCOVID study suggests Veyonda provides protection against progression of the severe inflammation associated with a worsening of the disease.\n<\/p>\n

\n\u201cUntil enough people are vaccinated to achieve global herd immunity in the face of waves of emerging mutant strains of the virus, millions of people are likely to continue to suffer severe COVID-19 disease involving major disabilities and death,\u201d said Noxopharm CEO Graham Kelly<\/a>. \u201cThat is where we see Veyonda playing a key role, with its STING blocking action stopping the destructive inflammatory process in patients with moderate COVID-19. The interim data released today points to Veyonda delivering on this promise.\u201d\n<\/p>\n

\nThe major challenge for hospital services during the current pandemic is the high level of care required for those patients experiencing rapid deterioration of lung function, leading to acute respiratory distress syndrome, septic shock, and major disabilities or death. A key factor associated with disease worsening is the excessive production of inflammatory factors normally invoked to facilitate tissue repair and combat infection in a process known as the cytokine storm.\n<\/p>\n

\nBiomarker data from the top Veyonda dose cohort is expected within the next few weeks. That will be followed by a review of the final clinical data on completion of treatment of the final patient. Clinical status (WHO COVID-19 grade, comorbidities) and other therapies will be considered, and after reviewing all the data, the Company will then consult with government, regulatory, medical, and business development advisors.\n<\/p>\n

About Noxopharm <\/b><\/p>\n

Noxopharm<\/a> Limited (ASX:NOX) is an Australian clinical-stage drug development company focused on the treatment of cancer and septic shock. Veyonda\u00ae is the Company\u2019s first pipe-line drug candidate currently in Phase 2 clinical trialing. Veyonda has two main drug actions \u2013 a moderating effect on the ceramide\/sphingosine-1-phosphate balance and inhibition of STING signaling. Activity against the former target contributes to its dual-acting oncotoxic and immuno-oncology functions designed to enhance the effectiveness and safety of standard oncology treatments, i.e., chemotherapies, radiotherapy and immune checkpoint inhibitors. Activity against the latter target provides an anti-inflammatory effect, also contributing to an anti-cancer action, but also potentially blocking septic shock.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20210427005330\/en\/<\/a><\/span><\/p>\n

\nJane Byram
\n
SCORR Marketing
\n
+1-512-626-2758
\n
jane@scorrmarketing.com<\/a><\/p>\n

KEYWORDS:<\/b> New York China India Australia North America Asia Pacific Japan United States Australia\/Oceania<\/p>\n

INDUSTRY KEYWORDS:<\/b> Research General Health Pharmaceutical Oncology Infectious Diseases Hospitals Clinical Trials Science Biotechnology Alternative Medicine Other Science Health<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Clinical Data Shows Noxopharm\u2019s Veyonda\u00ae May Prevent Cytokine Storm SYDNEY–(BUSINESS WIRE)– Australian clinical-stage drug development company Noxopharm Limted (ASX:NOX) today announced that in a cohort of 18 patients with moderately severe cases of COVID-19, interim data in its NOXCOVID study suggests Veyonda provides protection against progression of the severe inflammation associated with a worsening of the disease. \u201cUntil enough people are vaccinated to achieve global herd immunity in the face of waves of emerging mutant strains of the virus, millions of people are likely to continue to suffer severe COVID-19 disease involving major disabilities and death,\u201d said Noxopharm CEO Graham Kelly. \u201cThat is where we see Veyonda playing a key role, with its STING blocking action stopping the destructive inflammatory … <\/p>\n

Continue reading “Clinical Data Shows Noxopharm\u2019s Veyonda\u00ae May Prevent Cytokine Storm”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-482226","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nClinical Data Shows Noxopharm\u2019s Veyonda\u00ae May Prevent Cytokine Storm - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/clinical-data-shows-noxopharms-veyonda-may-prevent-cytokine-storm\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Clinical Data Shows Noxopharm\u2019s Veyonda\u00ae May Prevent Cytokine Storm - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Clinical Data Shows Noxopharm\u2019s Veyonda\u00ae May Prevent Cytokine Storm SYDNEY–(BUSINESS WIRE)– Australian clinical-stage drug development company Noxopharm Limted (ASX:NOX) today announced that in a cohort of 18 patients with moderately severe cases of COVID-19, interim data in its NOXCOVID study suggests Veyonda provides protection against progression of the severe inflammation associated with a worsening of the disease. \u201cUntil enough people are vaccinated to achieve global herd immunity in the face of waves of emerging mutant strains of the virus, millions of people are likely to continue to suffer severe COVID-19 disease involving major disabilities and death,\u201d said Noxopharm CEO Graham Kelly. \u201cThat is where we see Veyonda playing a key role, with its STING blocking action stopping the destructive inflammatory … Continue reading "Clinical Data Shows Noxopharm\u2019s Veyonda\u00ae May Prevent Cytokine Storm"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/clinical-data-shows-noxopharms-veyonda-may-prevent-cytokine-storm\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-27T12:04:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210427005330r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clinical-data-shows-noxopharms-veyonda-may-prevent-cytokine-storm\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clinical-data-shows-noxopharms-veyonda-may-prevent-cytokine-storm\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Clinical Data Shows Noxopharm\u2019s Veyonda\u00ae May Prevent Cytokine Storm\",\"datePublished\":\"2021-04-27T12:04:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clinical-data-shows-noxopharms-veyonda-may-prevent-cytokine-storm\\\/\"},\"wordCount\":455,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clinical-data-shows-noxopharms-veyonda-may-prevent-cytokine-storm\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210427005330r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clinical-data-shows-noxopharms-veyonda-may-prevent-cytokine-storm\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clinical-data-shows-noxopharms-veyonda-may-prevent-cytokine-storm\\\/\",\"name\":\"Clinical Data Shows Noxopharm\u2019s Veyonda\u00ae May Prevent Cytokine Storm - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clinical-data-shows-noxopharms-veyonda-may-prevent-cytokine-storm\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clinical-data-shows-noxopharms-veyonda-may-prevent-cytokine-storm\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210427005330r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2021-04-27T12:04:13+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clinical-data-shows-noxopharms-veyonda-may-prevent-cytokine-storm\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clinical-data-shows-noxopharms-veyonda-may-prevent-cytokine-storm\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clinical-data-shows-noxopharms-veyonda-may-prevent-cytokine-storm\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210427005330r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210427005330r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clinical-data-shows-noxopharms-veyonda-may-prevent-cytokine-storm\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Clinical Data Shows Noxopharm\u2019s Veyonda\u00ae May Prevent Cytokine Storm\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Clinical Data Shows Noxopharm\u2019s Veyonda\u00ae May Prevent Cytokine Storm - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/clinical-data-shows-noxopharms-veyonda-may-prevent-cytokine-storm\/","og_locale":"en_US","og_type":"article","og_title":"Clinical Data Shows Noxopharm\u2019s Veyonda\u00ae May Prevent Cytokine Storm - Market Newsdesk","og_description":"Clinical Data Shows Noxopharm\u2019s Veyonda\u00ae May Prevent Cytokine Storm SYDNEY–(BUSINESS WIRE)– Australian clinical-stage drug development company Noxopharm Limted (ASX:NOX) today announced that in a cohort of 18 patients with moderately severe cases of COVID-19, interim data in its NOXCOVID study suggests Veyonda provides protection against progression of the severe inflammation associated with a worsening of the disease. \u201cUntil enough people are vaccinated to achieve global herd immunity in the face of waves of emerging mutant strains of the virus, millions of people are likely to continue to suffer severe COVID-19 disease involving major disabilities and death,\u201d said Noxopharm CEO Graham Kelly. \u201cThat is where we see Veyonda playing a key role, with its STING blocking action stopping the destructive inflammatory … Continue reading \"Clinical Data Shows Noxopharm\u2019s Veyonda\u00ae May Prevent Cytokine Storm\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/clinical-data-shows-noxopharms-veyonda-may-prevent-cytokine-storm\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-27T12:04:13+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210427005330r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clinical-data-shows-noxopharms-veyonda-may-prevent-cytokine-storm\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clinical-data-shows-noxopharms-veyonda-may-prevent-cytokine-storm\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Clinical Data Shows Noxopharm\u2019s Veyonda\u00ae May Prevent Cytokine Storm","datePublished":"2021-04-27T12:04:13+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clinical-data-shows-noxopharms-veyonda-may-prevent-cytokine-storm\/"},"wordCount":455,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clinical-data-shows-noxopharms-veyonda-may-prevent-cytokine-storm\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210427005330r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clinical-data-shows-noxopharms-veyonda-may-prevent-cytokine-storm\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/clinical-data-shows-noxopharms-veyonda-may-prevent-cytokine-storm\/","name":"Clinical Data Shows Noxopharm\u2019s Veyonda\u00ae May Prevent Cytokine Storm - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clinical-data-shows-noxopharms-veyonda-may-prevent-cytokine-storm\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clinical-data-shows-noxopharms-veyonda-may-prevent-cytokine-storm\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210427005330r1&sid=flmnd&distro=nx&lang=en","datePublished":"2021-04-27T12:04:13+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clinical-data-shows-noxopharms-veyonda-may-prevent-cytokine-storm\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/clinical-data-shows-noxopharms-veyonda-may-prevent-cytokine-storm\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clinical-data-shows-noxopharms-veyonda-may-prevent-cytokine-storm\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210427005330r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210427005330r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clinical-data-shows-noxopharms-veyonda-may-prevent-cytokine-storm\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Clinical Data Shows Noxopharm\u2019s Veyonda\u00ae May Prevent Cytokine Storm"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/482226","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=482226"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/482226\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=482226"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=482226"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=482226"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}